Investing.com | Author Vlad Schepkov
Published May 15, 2023 22:48
Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: new data from X4 Pharma, upcoming review dates for Krystal Biotech, and a torrent of news set for release at an annual biotech conference.
When this news comes out, Start your 7-day free trial to see for yourself.
h2 Investors hyped up for fresh X4 Pharmaceuticals data/h2Keep an eye on X4 Pharma (NASDAQ:XFOR) on Tuesday, as the company is set to host a presentation of additional Phase 3 data for mavorixafor, its candidate for WHIM Syndrome.
The company had already reported positive Phase 3 results for the drug back in November 2022, and mavorixafor achieved both primary and key secondary endpoints. Nonetheless, investors appear hyped up for the upcoming presentation, as shares have rocketed 80% since early April.
XFOR said it remains on track to submit a New Drug Application (NDA) to the FDA early in the second half of 2023. The stock currently has 11 Buy ratings from various analysts with an average price target of $3.50.
Shares were recently changing hands at $1.47.
h2 Krystal Biotech's upcoming PDUFA date/h2Krystal Biotech (NASDAQ:KRYS) is gearing up for the PDUFA of B-VEC, its candidate to treat Epidermolysis Bullosa, on Friday. The company previously had the review date of Feb. 17, although that got pushed back to this coming Friday, May 19, following submission of additional manufacturing data to the FDA.
Heading into the decision, shares are up about 15% year to date to $88.16.
A total of 12 analysts currently cover the company, all with a Buy rating, and an average price target of $115.
Most recently, Stifel initiated coverage with a $102 price target, and called the B-VEC readout an "important milestone that we think warrants optimism."
h2 Drug from Genmab and AbbVie set for review/h2
Another PDUFA is scheduled for next weekend: Epcoritamab, a drug co-developed by AbbVie (NYSE:ABBV) and Genmab (NASDAQ:GMAB) to potentially treat diffuse large B-cell lymphoma, commonly known as DLBCL, is set for review next Sunday.
ABBV currently has 19 Buy ratings, 13 Holds, and 2 Sells. Its shares are down some 9% year to date to $147.15.
Genmab is up 3% from the start of the year to $41.69.
h2 A raft of news set for release at the ASGCT annual meeting/h2Last, but not least, American Society of Gene Cell Therapy (ASGCT) will be holding its 26th annual meeting from Tuesday to Saturday, and multiple companies are set to provide updates and release new data bits over the course of the meeting - which InvestingPro subscribers will receive in real time:
Tuesday, May 16:
Wednesday, May 17:
Thursday, May 18:
Friday, May 19:
Saturday, May 20:
Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro .
Start your free 7-day trial now .
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.